Stock Scorecard

Stock Summary for Replimune Group Inc (REPL) - $4.43 as of 10/15/2025 7:58:38 AM EST

Total Score

10 out of 30

Safety Score

29 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for REPL

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for REPL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for REPL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for REPL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for REPL (29 out of 100)

Stock Price Rating (Max of 10) 3
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 2
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for REPL

REPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Replimune Group ( NASDAQ:REPL ) 10/8/2025 10:24:00 PM
REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug 9/24/2025 3:06:00 PM
REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit - Replimune Group ( NASDAQ:REPL ) 9/22/2025 2:31:00 PM
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune - Replimune Group ( NASDAQ:REPL ) 9/21/2025 11:40:00 AM
REPL DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class... 9/21/2025 11:12:00 AM
REPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - REPL - Replimune Group ( NASDAQ:REPL ) 9/21/2025 10:09:00 AM
Class Action Filed Against Replimune Group, Inc. ( REPL ) Seeking Recovery for Investors - Contact Levi & Korsinsky - Replimune Group ( NASDAQ:REPL ) 9/19/2025 8:46:00 PM
Why Replimune Stock Was Tumbling Again Today 9/19/2025 8:08:00 PM
REPL 3-DAY DEADLINE ALERT: Replimune ( REPL ) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman - Replimune Group ( NASDAQ:REPL ) 9/19/2025 1:00:00 PM
This United Parcel Service Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - 89bio ( NASDAQ:ETNB ) , Replimune Group ( NASDAQ:REPL ) 9/19/2025 12:06:00 PM

Financial Details for REPL

Company Overview
Ticker REPL
Company Name Replimune Group Inc
Country USA
Description Replimune Group, Inc. is a pioneering biotechnology company based in Woburn, Massachusetts, focused on the development of oncolytic immunogenic therapies for the treatment of cancer. Leveraging its innovative Immuno-Oncology platform, Replimune aims to harness the power of the immune system to selectively target and destroy tumor cells while promoting robust anti-tumor immune responses. The company is advancing multiple clinical programs that illustrate the effectiveness of its proprietary therapies, positioning itself as a leader in the rapidly evolving field of cancer treatment.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/11/2025

Stock Price History
Last Day Price 4.43
Price 4 Years Ago 27.10
Last Day Price Updated 10/15/2025 7:58:38 AM EST
Last Day Volume 3,731,379
Average Daily Volume 4,118,155
52-Week High 17.00
52-Week Low 2.68
Last Price to 52 Week Low 65.30%

Valuation Measures
Trailing PE N/A
Industry PE 22.31
Sector PE 40.41
5-Year Average PE -4.70
Free Cash Flow Ratio 3.54
Industry Free Cash Flow Ratio 14.26
Sector Free Cash Flow Ratio 29.23
Current Ratio Most Recent Quarter 6.94
Total Cash Per Share 1.25
Book Value Per Share Most Recent Quarter 4.33
Price to Book Ratio 1.08
Industry Price to Book Ratio 29.98
Sector Price to Book Ratio 32.01
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 30.64
Sector Price to Sales Ratio Twelve Trailing Months 15.78
Analyst Buy Ratings 2
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 78,056,000
Market Capitalization 345,788,080
Institutional Ownership 104.90%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -14.60%
Reported EPS 12 Trailing Months -3.24
Reported EPS Past Year -0.95
Reported EPS Prior Year -3.07
Net Income Twelve Trailing Months -280,218,000
Net Income Past Year -247,297,000
Net Income Prior Year -215,794,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet
Total Cash Most Recent Quarter 97,373,000
Total Cash Past Year 111,119,000
Total Cash Prior Year 74,457,000
Net Cash Position Most Recent Quarter 50,581,000
Net Cash Position Past Year 64,742,000
Long Term Debt Past Year 46,377,000
Long Term Debt Prior Year 44,809,000
Total Debt Most Recent Quarter 46,792,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.88
Total Stockholder Equity Past Year 415,843,000
Total Stockholder Equity Prior Year 374,508,000
Total Stockholder Equity Most Recent Quarter 336,715,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -227,857,000
Free Cash Flow Per Share Twelve Trailing Months -2.92
Free Cash Flow Past Year -198,937,000
Free Cash Flow Prior Year -191,129,000

Options
Put/Call Ratio 2.37
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.24
MACD Signal -0.36
20-Day Bollinger Lower Band 1.78
20-Day Bollinger Middle Band 7.08
20-Day Bollinger Upper Band 12.39
Beta 0.42
RSI 46.95
50-Day SMA 9.80
150-Day SMA 13.10
200-Day SMA 14.53

System
Modified 10/14/2025 7:59:05 AM EST